Long-term follow-up of HIV-1-infected adults who received the F4/AS01(B) HIV-1 vaccine candidate in two randomised controlled trials

Harrer T, Dinges W, Roman F (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Vaccine Elsevier

Book Volume: 36

Pages Range: 2683-2686

Journal Issue: 19

DOI: 10.1016/j.vaccine.2018.03.043

Abstract

This Phase I/II open, long-term follow-up study was conducted in antiretroviral therapy (ART)-naive (N = 212) and ART-treated (N = 19) human immunodeficiency virus 1 (HIV-1)-infected adults, who received an HIV-1 investigational vaccine (F4/AS01(B)) or placebo in two previous studies (NCT00814762 and NCT01218113). After a minimum of two years and a maximum of four years of follow-up postvaccination per patient, no significant differences were observed between F4/AS01(B) and placebo groups in terms of viral load, CD4(+) T-cell count and incidence of specific clinical events. Vaccine-induced polyfunctional CD4(+) T-cells persisted up to study end and no relevant vaccine-related safety events were reported in F4/AS01(B) groups. (C) 2018 The Authors. Published by Elsevier Ltd.

Authors with CRIS profile

Thomas Harrer Professur für Innere Medizin mit dem Schwerpunkt Immundefizienz

Involved external institutions

GlaxoSmithKline (GSK) (Belgium)

Belgium (BE) Seattle Infectious Disease Clinic

United States (USA) (US)

How to cite

APA:

Harrer, T., Dinges, W., & Roman, F. (2018). Long-term follow-up of HIV-1-infected adults who received the F4/AS01(B) HIV-1 vaccine candidate in two randomised controlled trials. Vaccine, 36(19), 2683-2686. https://doi.org/10.1016/j.vaccine.2018.03.043

MLA:

Harrer, Thomas, Warren Dinges, and Francois Roman. "Long-term follow-up of HIV-1-infected adults who received the F4/AS01(B) HIV-1 vaccine candidate in two randomised controlled trials." Vaccine 36.19 (2018): 2683-2686.

BibTeX: Download